A Phase III Study to Investigate the Efficacy and Safety of Elecoglipron Alone or in Combination With Dapagliflozin Compared With Placebo in Adults With Type 2 Diabetes Mellitus

How this study is set up

The points below are drawn from the public registry record for this study. Each one cites the field or sentence it came from. A dash (—) means the record does not state something — not that it is missing or wrong. Many well-run studies, especially small ones, leave some of these blank.

• ✓
  Present: Registered before enrolment beganFirst posted 2026-06-23; recorded start 2026-07-06
• ✓
  Present: Has a defined primary outcomeA primary outcome measure is listed in the record
• ✓
  Present: The primary outcome states a time frameThe primary outcome measure records a time frame
• ✓
  Present: Participants are randomly assignedAllocation is recorded as randomised
• ✓
  Present: Has a comparison groupThe record lists a placebo or comparator arm, or more than one study arm
• ✓
  Present: Uses blinding (masking)A masking level is recorded in the record
• —
  Not stated: An ethics committee is not stated in the registry recordThis registry's ingested record has no ethics-committee field
• —
  Not stated: Regulatory oversight (such as an IND or IDE) is not stated in the registry recordThis registry's ingested record has no regulatory-authorisation field
• —
  Not stated: A data monitoring committee is not stated in the registry recordThis registry's ingested record has no data-monitoring-committee fieldA data monitoring committee is not required for many smaller studies, and its absence here is not unusual.
• ✓
  Present: No cost to participants is mentioned in the recordChecked the summary, description and eligibility text; no cost-to-participant phrase found
• ✓
  Present: Sponsor has 1019 other studies in this databaseCounted from the lead sponsor named in the record (AstraZeneca)
• ✓
  Present: Sponsor has posted results for at least one studyBased on the sponsor’s studies in this database

• The record lists 1 condition.
• Lead sponsor type recorded as: industry.
• Intervention regulatory context: investigational, within a phased regulatory pathway.

These are facts from the public registry record, not a judgement about the study. Discuss any trial with your own doctor before taking part.

What these facts mean, and what to ask · ruleset v1